Genelux: 2nd Half Of 2025 PRROC Data Is Major Inflection Point

Core Insights - Genelux Corporation (NASDAQ: GNLX) is preparing for a significant milestone in the upcoming year, with topline results expected from its phase 3 OnPrime/GOG-3076 registrational study for the oncolytic immunotherapy drug Olvi-Vec [2] Company Overview - Genelux Corporation is focused on developing innovative cancer therapies, particularly through its oncolytic immunotherapy approach [2] Investment Analysis - The Biotech Analysis Central service offers extensive resources for investors, including a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks [2]